/QNTM
QNTM Stock - Quantum BioPharma Ltd.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$8.89+0.79%
+$0.07 (+0.79%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $9.78
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QNTM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.80 – $8.98
TARGET (TP)$10.22
STOP LOSS$8.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.71
52W High$38.25
52W Low$2.89
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,136,260 | $-23,789,498 | $-27,429,611 | $-33,743,660 | $-30,691,088 |
| Net Income | $-14,202,724 | $-17,902,179 | $-23,606,828 | $-35,285,429 | $-31,799,793 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-12.49 | $-29.39 | $-39.62 | $-65.63 | $-171.62 |
Company Overview
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
QNTMBeat Rate
25%
Last 8 quarters
Avg Surprise
-340.3%
EPS vs Estimate
Beats / Misses
2/5
1 met exactly
Latest EPS
$-1.25
Q4 2025
EPS Surprise History
Q4 23
+78.5%
$-1.95vs$-9.09
Q1 24
+99.6%
$-0.04vs$-9.31
Q2 24
0.0%
$-3.25vs$-3.25
Q3 24
-33.3%
$-5.20vs$-3.90
Q1 25
-261.3%
$-2.89vs$-0.80
Q2 25
-281.1%
$-1.41vs$-0.37
Q3 25
-1800.0%
$-3.23vs$-0.17
Q4 25
-525.0%
$-1.25vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.20 | $-1.25 | -525.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.17 | $-3.23 | -1800.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.37 | $-1.41 | -281.1% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.80 | $-2.89 | -261.3% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-3.90 | $-5.20 | -33.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-3.25 | $-3.25 | 0.0% | = MET |
Q1 2024 | Mar 28, 2024 | $-9.31 | $-0.04 | +99.6% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-9.09 | $-1.95 | +78.5% | ✓ BEAT |
Q3 2023 | Jul 20, 2023 | — | $-9.31 | — | — |
Q1 2023 | Mar 31, 2023 | — | — | — | — |
Q4 2022 | Nov 11, 2022 | — | — | — | — |
Q4 2021 | Nov 15, 2021 | — | $-9.57 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-22.88 | — | — |
Latest News
Quantum BioPharma To Broadcast Three-Part Series About Allegations Of Stock Market Manipulation Against Company
📉 NegativeBenzinga•Nov 25, 2025, 09:02 PM
Quantum BioPharma Q3 EPS $(1.25) Misses $(0.08) Estimate
📉 NegativeBenzinga•Nov 7, 2025, 01:47 PM
Quantum BioPharma Denies Unsubstantiated Securities Investigation Allegations, Vows Legal Action Against Law Firms
📉 NegativeBenzinga•Oct 14, 2025, 12:25 PM
Reported Earlier: Quantum Biopharma Reveals Cash Reward Of Up To $7M for Proof Of Market Manipulation In Its Stock
📉 NegativeBenzinga•Oct 8, 2025, 02:20 PM
Reported Earlier: Quantum BioPharma Sets Record Date Of October 27, 2025 For Litigation-Linked Contingent Value Rights Tied to Potential $700M Lawsuit Proceeds
➖ NeutralBenzinga•Oct 3, 2025, 02:54 PM
Quantum Biopharma shares are trading higher after the company announced it received two key final reports related to its potential breakthrough drug for Multiple Sclerosis.
📈 PositiveBenzinga•Oct 2, 2025, 06:46 PM
Quantum BioPharma Receives Two Key Final Reports Of Potential Breakthrough Drug For Multiple Sclerosis: 90-Day Oral Toxicity Study Report And Toxicokinetic Study Report For Lucid-21-302
📈 PositiveBenzinga•Oct 2, 2025, 11:58 AM•Also:
Quantum BioPharma Secures Health Canada Product License For Qlarity
📈 PositiveBenzinga•Sep 18, 2025, 12:16 PM
Quantum Biopharma shares are trading higher after Kingswood Capital Partners initiated coverage on the stock with a Buy rating and announced a $45 price target.
📈 PositiveBenzinga•Sep 10, 2025, 04:54 PM
Quantum BioPharma Wins Buy Rating And $45 Forecast From Kingswood On Promise Of MS Drug Lucid-MS
📈 PositiveBenzinga•Sep 10, 2025, 11:09 AM•Also:
Quantum BioPharma announces private placement
➖ NeutralSeeking Alpha•Jun 27, 2025, 08:35 PM
Frequently Asked Questions about QNTM
What is QNTM's current stock price?
Quantum BioPharma Ltd. (QNTM) is currently trading at $8.89 per share. The stock has moved +0.79% today.
What is the analyst price target for QNTM?
No analyst price targets are currently available for this stock.
What sector is Quantum BioPharma Ltd. in?
Quantum BioPharma Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is QNTM's market cap?
Quantum BioPharma Ltd. has a market capitalization of $0.03 billion, making it a small-cap company.
Does QNTM pay dividends?
No, Quantum BioPharma Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
CPIX
Cumberland Pharmaceuticals Inc.
$4.41
Mkt Cap: $0.1B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RMTI
Rockwell Medical, Inc.
$0.85
Mkt Cap: $0.0B
RNTX
Rein Therapeutics Inc.
$1.42
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to QNTM for comparison